MHRA Seeks Comments on Rare Disease Framework

Rare Daily Staff

The United Kingdom has unveiled sweeping plans to accelerate the development and approval of treatments for rare diseases.

The Medicines and Healthcare products Regulatory Agency (MHRA) launched a public consultation on a proposed regulatory framework designed to make it faster and less costly to bring rare disease therapies to market.

At the heart of the proposal is a shift away from traditional drug development models, which are typically built for common diseases with large patient populations. Instead, the MHRA is proposing a more flexible, “risk-proportionate” approach tailored to conditions affecting up to one in 50,000 people, where standard clinical trials are often impractical.

A central feature of the plan is a new pathway called the Investigational Marketing Authorization. This would allow promising therapies to reach patients earlier, even when evidence is still emerging, while continuing to collect data on safety and effectiveness. Treatments would still require approval from the National Institute for Health and Care Excellence (NICE) before being used in the National Health Service.

Health officials said the approach could shorten development timelines, reduce costs, and encourage more companies to invest in rare disease research, which is an area that has historically struggled to attract funding due to small patient populations and scientific complexity.

“For the millions of people in the UK living with a rare disease, and for the families and carers who support them, the search for effective treatment can be long, exhausting and deeply uncertain,” said Public Health Minister Sharon Hodgson. “These landmark proposals represent an important step towards a more agile and compassionate system – one that recognizes the unique challenges of rare disease research while maintaining the highest standards of patient safety.”

Rare diseases collectively represent a significant health burden. Fewer than 5 percent have an approved treatment, and patients often endure diagnostic journeys lasting more than five years. The impact is especially severe in children, with around 30 percent of those affected dying before the age of five. Despite advances in genetics and biotechnology, regulatory systems have struggled to keep pace with innovation.

The MHRA developed the framework in collaboration with a newly formed Rare Disease Consortium, which includes patient groups, academic researchers, pharmaceutical companies, and healthcare organizations. The goal, officials say, is to ensure that the system reflects the realities faced by patients and developers alike.

Industry and patient advocates have broadly welcomed the proposal. Nick Meade, chief executive of Genetic Alliance UK, called it an “ambitious undertaking” that could open the door to new treatment approaches. Others emphasized that faster regulatory timelines could make a meaningful difference in patients’ lives, where delays can be critical.

The economic stakes are also significant. Delayed diagnoses alone are estimated to cost the UK £340 million annually, with broader health-related and productivity losses reaching billions more.

Former Prime Minister David Cameron, who has personal experience with rare disease through his late son Ivan, described the announcement as a “hopeful step” toward a system that matches the urgency of scientific progress. “What patients and families need now is a system that can move with the same urgency as the science,” he said.

The consultation is open until July 20, 2026, and the MHRA is encouraging input from patients, families, clinicians, and researchers. The feedback will help shape the final version of the framework, which could position the UK as a global leader in rare disease innovation.

Photo: Former Prime Minister David Cameron, whose son Ivan died of a rare disease.